IKKβ binds NLRP3 providing a shortcut to inflammasome activation for rapid immune responses

Signal Transduction and Targeted Therapy (2022) 7:355

Dear Editor,

A rapid immune response to signals released from pathogen and injuries is critical for maintaining tissue integrity and restoring homeostasis. This response is largely mediated by the concerted action of pattern recognition receptors (PRRs). Such cooperation has been described for Toll-like receptors (TLRs) and NACHT, LRR, and pyrin domain-containing protein 3 (NLRP3), but the underlying molecular mechanisms remain incompletely understood. Inflammamasomes are multi-protein complexes defined by a cytosolic innate immune sensor, usually a PRR, which recruits the adaptor molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) to activate the effector caspase-1 leading to the release of matured IL-1β and IL-18. Active caspase-1 further cleaves gasdermin D (GSDMD) allowing the N-terminal domain of GSDMD (GSDMD-N) to form pores in the plasma membrane, thus facilitating the release of matured IL-1β and IL-18. Pore-forming GSDMD-N further induces pyroptosis, an inflammatory form of cell death.1 NLRP3 inflammasome activation typically entails NF-κB-driven transcriptional priming, which in turn licenses the cell for inflammasome assembly and activation.2 A previously discussed paradigm of rapid inflammasome assembly without the requirement for NF-κB-driven transcriptional priming involves simultaneous engagement of TLRs and NLRP3.2,3 While increasingly recognized, the molecular mechanisms and ensuing biological effects remain largely undefined. Recent work has demonstrated a role of IKKβ in activation of the NLRP3 inflammasome by recruiting NLRP3 to the dispersed trans-Golgi network.4 Given the activating effect of TLR signaling on IKK and the central role of NF-κB in inflammasome signaling,5,6 we scrutinized whether IKK could directly activate the inflammasome on top of its effects on priming.

To systematically study the role of IKKβ in inflammasome activation beyond transcriptional priming, we assessed possible interactions between IKK and the inflammasome. Co-immunoprecipitation experiments in transfected HEK293 cells revealed binding of IKKβ to NLRP3 but not NLRC4, NLRP1, and AIM2 (Fig. 1a, b). To determine the specific domains of NLRP3 interacting with IKKβ, we co-transfected HA-IKKβ with Flag-tagged full-length or mutant NLRP3 and subjected the lysate to immunoprecipitation. We found that IKKβ binds to full-length as well as mutant NLRP3 lacking the amino-terminal pyrin domain, the singly expressed NACHT and LRR domains, but not the PYD (Fig. 1c, d). Next, we examined whether the enzymatic activity of IKKβ is required for this interaction and found that the wild-type, constitutively active, and catalytically inactive IKKβ all bind to NLRP3 (Supplementary Fig. 1a). An appreciable proportion of NLRP3 was found in IKKβ precipitates and vice versa (Supplementary Fig. 1b, c). As demonstrated by confocal microscopy, IKKβ and NLRP3 colocalized in bone marrow-derived macrophages (BMDMs) transfected with HA-IKKβ and stimulated with LPS and nigericin (Fig. 1e). Importantly, IKKβ promoted the oligomerization of NLRP3 (Fig. 1f), possibly in part through effects on the recruitment of NLRP3 to the dispersed TGN.4,5 To further analyze this interaction at endogenous levels and determine the effect of inflammasome activation on this interaction, we treated human THP-1 macrophages with LPS and NLRP3 activators (nigericin or ATP) and subjected the lysate to immunoprecipitation. Consistent with the results in HEK293 cells, we found that IKKβ binds to NLRP3 at endogenous levels in THP-1 macrophages stimulated with LPS and NLRP3 activators or left unstimulated, indicating the constitutive nature of this interaction (Fig. 1g). We found no binding of p38 MAP Kinase to NLRP3 (Supplementary Fig. 1d), further supporting the specificity of the identified interactions. As a last step to corroborate this interaction, we performed microscale thermophoresis (MST) analysis by titrating MST-Red-NLRP3 against increasing concentrations of IKKβ. The obtained curve revealed a direct interaction between IKKβ and NLRP3 and a KD value of 1.43 ± 0.35 µM was derived for the binding affinity (Fig. 1h). Collectively, these findings identify IKKβ as an interactor of NLRP3 promoting its oligomerization.

To detail the consequence of this interaction, we pharmacologically inhibited IKKβ with TCPA-1 in BMDMs. The dose of TCPA-1 used was chosen after titration (Supplementary Fig. 2a–e). Quantitative proteomic profiling of IKKβ-inhibited BMDMs revealed a perturbation of proteins related to signaling in the immune system and pyroptosis including Gsdmdc1, Dhhx9, Cycs, and Casp8 (Supplementary Fig. 3a–d). Given this evidence and our data indicating that IKKβ binds NLRP3, we employed two treatment and stimulation paradigms to assess the effects of IKKβ inhibition on NLRP3 inflammasome activation. The first paradigm involved inhibition of IKKβ before LPS priming and nigericin stimulation (pre-priming inhibition), while the second involved LPS priming followed by IKKβ inhibition and subsequent nigericin activation (post-priming inhibition). The latter served as an attempt to examine the direct effect of IKKβ on inflammasome activation rather than priming. Post-priming inhibition of IKKβ in BMDMs resulted in reduced cleavage of caspase-1 and GSDMD (Supplementary Fig. 4a–e), which went along with reduced maturation and secretion of IL-1β and IL-18 (Supplementary Fig. 4f, g) and limited pyroptosis in macrophages as revealed by reduced LDH release (Supplementary Fig. 4h). Similar observations were made for pre-priming inhibition, when cells were treated with either TCPA-1 or siRNA-mediated knockdown of IKKβ (Supplementary Fig. 2f and 5a–i).

Next, we investigated the involvement of IKKβ in rapid assembly of the NLRP3 inflammasome by challenging cells simultaneously with LPS and nigericin for 60 min (Fig. 1i). Inhibition of IKKβ limited rapid assembly of the inflammasome as demonstrated by reduced NLRP3 oligomerization (Fig. 1j). Immunostaining with anti-caspase-1 and anti-ASC antibodies revealed caspase-1 and ASC in a high molecular-mass NLRP3 complex de

Received: 23 June 2022 Revised: 22 August 2022 Accepted: 7 September 2022

© The Author(s) 2022
Fig. 1  IKKβ binds NLRP3 to induce rapid inflammasome assembly and pyroptotic cell death. a–d HEK293 cells were transiently cotransfected with HA-tagged full-length IKKβ, Flag-tagged full-length or mutant NLRP3, and Flag-tagged full-length NLRC4, AIM2, or NLRP1. Shown are representative immunoblots depicting the binding of IKKβ to NLRP3, but not NLRC4, AIM2, and NLRP1 (a, b), and specific domains of NLRP3 (c, d). n = 3 to 4 independent experiments. e Determination of colocalization between IKKβ and NLRP3 in BMDMs by confocal microscopy. Shown are representative immunostainings of three independent experiments. Scale bar = 20 µm. f Representative immunoblot showing the assessment of NLRP3 oligomerization in transfected HEK293 cells stimulated with nigericin and analyzed by blue native PAGE. n = 3 independent experiments. g THP-1 macrophages were either stimulated with LPS (200 ng/mL) for 4 h and nigericin (5 µM) for 60 min or ATP (5 mM) for 30 min or left unstimulated. Shown is a representative immunoblot depicting the endogenous binding of IKKβ to NLRP3. n = 3 independent experiments. h Protein–protein interactions between IKKβ and NLRP3 were analyzed in solution applying microscale thermophoresis (MST). 50 nM MST-Red-NLRP3 was titrated against increasing concentrations of IKKβ. Plotted is the fraction of bound MST-Red-NLRP3 (fraction bound) over the indicated concentrations of IKKβ (log scale). Data are represented as mean ± SD, with 3–4 data points for each concentration of IKKβ. Two independent titrations measured in two separate sets of capillaries. i–q Simultaneous engagement of TLRs and NLRP3. BMDMs were treated with TPCA-1 (500 nM) for 1 h and were simultaneously stimulated with LPS (200 ng/mL) and nigericin (5 µM) for 1 h. i Experimental outline. j Representative immunoblot depicting caspase-1 cleavage. k Quantification of cleaved caspase-1 normalized to actin. n = 5 independent experiments. m Representative immunoblots of GSDMD cleavage. n Quantification of GSDMD cleavage normalized to actin. n = 6 independent experiments. o Measurement of LDH release. n = 3 independent experiments. p Determination of Zombie uptake. Shown are representative immunostainings of three independent experiments. Scale bar = 50 µm. q Quantification of Zombie uptake. Data are represented as mean ± SEM. Two-sided unpaired t test was used in the statistical analyses after testing for normality with Shapiro–Wilk Test.
complex. Pharmacological inhibition of IKKβ limited the formation of this large oligomeric complex (Supplementary Fig. 6a, b). IKKβ inhibition further decreased caspase-1 activation (Fig. 1k, l), reduced IL-18 release (Supplementary Fig. 5j, k), and GSDMD cleavage (Fig. 1m, n). This restricted the formation of pore-forming GSDMD-N to induce pyropoptosis in macrophages as demonstrated by reduced LDH release (Fig. 1o) and decreased uptake of Zombie NIR, an independent readout of pyropoptosis (Fig. 1p, q). Hence, aside from effects on transcriptional priming, IKKβ further bridges TLR and NLR signaling providing a “shortcut” to inflammasome activation for prompt immune response.

Taken together, the results presented here show that (i) IKKβ directly interacts with NLRP3; (ii) IKKβ promotes the oligomerization of NLRP3; and (iii) pharmacological inhibition of IKKβ reduces rapid caspase-1 activation and limits GSDMD cleavage to restrict macrophase pyropoptosis. Our findings thus provide a mechanistic explanation for rapid immune responses induced by the TLR-NLR signaling axis and implicate IKKβ as an essential regulator of pyropotic cell death. This should be accounted for when designing therapeutic strategies that block TLR-NLR signaling in order to avoid increased rates of infection as recently seen in therapeutic neutralization of IL-1β.6

DATA AVAILABILITY
All data and materials are presented in the main manuscript or supplementary materials and are available on request. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD036118.

ACKNOWLEDGEMENTS
We are grateful to Drs. Veit Hornung and Florian Schmidt for advice and sharing constructs. We thank Dr. Christian Behrends for his expertise on quantitative proteomics. This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG; CRC 1123 [B3], Df-722/16-1 [ID: 428668490], and Munich Cluster for Systems Neurology [SyNergy, EXC 2145]), and the Vascular Dementia Research Foundation to M. Dichgans. Y. Asare was supported by DFG (CRC 1123 [B3]). J. Bernhagen received funding from DFG/ERC 1123 [A3], DFG INST 409/209-1 FUOG, and DFG (EXC 2145 SyNergy). C. Weber was supported by DFG (CRC 1123 [A01 & A10]).

AUTHOR CONTRIBUTIONS
Y.A. and M.D. designed research; Y.A., M.S., L.Z., C.S., F.T., A.A., L.S., and M.B. performed research; Y.A., N.B., R.M., C.W., J.B., and M.D. analyzed data; Y.A. and M.D. wrote the paper.

REFERENCES
1. Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).
2. Lin, K. M. et al. IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation. Proc. Natl. Acad. Sci. USA 111, 775–780 (2014).
3. Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044–1066 (2020).
4. Nanda, S. K., Prescott, A. R., Figueras-Vadillo, C. & Cohen, P. IKKbeta is required for the formation of the NLRP3 inflammasome. EMBO Rep. 22, e50743 (2021).
5. Chen, J. & Chen, Z. J. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature 564, 71–76 (2018).
6. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

Correspondence: Yaw Asare (yaw.asare@med.uni-muenchen.de) or Martin Dichgans (martin.dichgans@med.uni-muenchen.de)

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41392-022-01189-3.

Competing interests: The authors declare no competing interests.

Ethics: Isolation of bone marrow-derived macrophages from mice were approved by the Institutional Animal Care Committee of Regierung von Oberbayern (ROB-55.2-2532.Vet.02-14-I87).

Yaw Asare1✉, Margarita Shnipova1, Luka Živkovic1, Christina Schlegl2, Federica Tosato3, Aralym Aronova4, Markus Brandhofer1, Laura Strohm5, Nathalie Beaufort1, Rainer Malik1, Christian Weber2, Jürgen Bernhagen1,2 and Martin Dichgans1,2✉
1Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany; 2Munich Cluster for Systems Neurology (SyNergy), Munich, Germany and 1Institute for Cardiovascular Prevention (IPEK), LMU, Munich, Germany

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.